WO2001044269A3 - Brain protein markers - Google Patents

Brain protein markers Download PDF

Info

Publication number
WO2001044269A3
WO2001044269A3 PCT/US2000/033903 US0033903W WO0144269A3 WO 2001044269 A3 WO2001044269 A3 WO 2001044269A3 US 0033903 W US0033903 W US 0033903W WO 0144269 A3 WO0144269 A3 WO 0144269A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein markers
brain protein
markers
discovered
targets
Prior art date
Application number
PCT/US2000/033903
Other languages
French (fr)
Other versions
WO2001044269A2 (en
WO2001044269A9 (en
WO2001044269B1 (en
Inventor
Nancy Johnston-Wilson
Christina Sims
Jean-Paul Hofmann
N Leigh Anderson
Andrew Shore
Robert Yolken
E Fuller Torrey
Original Assignee
Large Scale Proteomics Corp
John Hopkins Unviersity
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Large Scale Proteomics Corp, John Hopkins Unviersity filed Critical Large Scale Proteomics Corp
Priority to AU25794/01A priority Critical patent/AU2579401A/en
Publication of WO2001044269A2 publication Critical patent/WO2001044269A2/en
Publication of WO2001044269A3 publication Critical patent/WO2001044269A3/en
Publication of WO2001044269B1 publication Critical patent/WO2001044269B1/en
Publication of WO2001044269A9 publication Critical patent/WO2001044269A9/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Abstract

Protein markers for various psychiatric and neurological disorders were discovered. Diagnostic assays for these conditions were based on the levels of individual or combinations. The markers are targets or drug discovery for therapeutic and prophylactic uses.
PCT/US2000/033903 1999-12-17 2000-12-15 Brain protein markers WO2001044269A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU25794/01A AU2579401A (en) 1999-12-17 2000-12-15 Brain protein markers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17228699P 1999-12-17 1999-12-17
US60/172,286 1999-12-17

Publications (4)

Publication Number Publication Date
WO2001044269A2 WO2001044269A2 (en) 2001-06-21
WO2001044269A3 true WO2001044269A3 (en) 2001-12-13
WO2001044269B1 WO2001044269B1 (en) 2002-01-10
WO2001044269A9 WO2001044269A9 (en) 2002-05-23

Family

ID=22627065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033903 WO2001044269A2 (en) 1999-12-17 2000-12-15 Brain protein markers

Country Status (2)

Country Link
AU (1) AU2579401A (en)
WO (1) WO2001044269A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7236888B2 (en) 1998-03-06 2007-06-26 The Regents Of The University Of California Method to measure the activation state of signaling pathways in cells
AU2002217839A1 (en) * 2000-11-22 2002-06-03 The Regents Of The University Of California A method to measure the activation state of signaling pathways in cells
US7691645B2 (en) * 2001-01-09 2010-04-06 Agilent Technologies, Inc. Immunosubtraction method
US8068987B2 (en) * 2001-08-13 2011-11-29 Bg Medicine, Inc. Method and system for profiling biological systems
US7074576B2 (en) * 2001-11-23 2006-07-11 Syn X Pharma, Inc. Protein biopolymer markers indicative of alzheimer's disease
US7026129B2 (en) * 2001-11-23 2006-04-11 Syn X Pharma, Inc. IG lambda biopolymer markers predictive of Alzheimers disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5220013A (en) * 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US5387742A (en) * 1990-06-15 1995-02-07 Scios Nova Inc. Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5220013A (en) * 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5387742A (en) * 1990-06-15 1995-02-07 Scios Nova Inc. Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOHNSTON-WILSON ET AL.: "Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder and major depressive disorder", MOL. PSYCHIATRY, vol. 5, 2000, pages 142 - 149, XP002943682 *
LUBEC ET AL.: "Expression of the dihydropyrimidase related protein 2 (DRP-2) in down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level", J. NEURAL TRANS., vol. 57, no. SUPPLEMENT, 1999, pages 161 - 177, XP002943683 *

Also Published As

Publication number Publication date
WO2001044269A2 (en) 2001-06-21
WO2001044269A9 (en) 2002-05-23
AU2579401A (en) 2001-06-25
WO2001044269B1 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
WO1998040055A3 (en) Anti-epileptogenic agents
AU2001236904A1 (en) Deep brain stimulation system for the treatment of parkinson's disease or other disorders
AU4119899A (en) System for treating the fundus of an eye
CA2381770A1 (en) Human ctla-4 antibodies and their uses
WO2002099040A3 (en) Igs as modifiers of the p53 pathway and methods of use
WO2002099044A3 (en) B3galts as modifiers of the p53 pathway and methods of use
AU6462500A (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2001006989A3 (en) Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
AU6406996A (en) Compositions for the treatment and diagnosis of body weight disorders, including obesity
CA2368843A1 (en) Neurotrophic substituted pyrimidines
WO2001098279A3 (en) Bis-arylsulfones
CA2257010A1 (en) Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia
AU2396000A (en) Treatment of hyperproliferative disorders using casein kinase
AU6910600A (en) Methods for the treatment of mental disorders
HK1029942A1 (en) Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma.
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
AU4674797A (en) Phenylalaninol derivatives for the treatment of central nervous system disorders
WO2002073208A3 (en) Anti-epileptogenic agents
WO2002098889A3 (en) MAP3Ks AS MODIFIER OF THE p53 PATHWAY AND METHODS OF USE
CA2347863A1 (en) Treatment of disorders of the outer retina
WO2001044269A3 (en) Brain protein markers
AU4127597A (en) Biochemical markers of the human endometrium
WO2003004517A3 (en) Peyers's patch and/or m-celle targeting ligands
HK1038510A1 (en) Use of neurotrophic factor stimulators for the treamtent of ophthalmic neurodegenerative diseases.
ATE256126T1 (en) 5-HETEROATOM-ALKYL SUBSTITUTED 3-OXO-PYRIDO(1,2-A)BENZIMIDAZOLE-4-CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES 1/7-7/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP